c 2015 Your Healthcare Place

We are currently taking new patients and would be happy to serve the helathcare needs of your family. 

Helpful Links

1813 Hinkle Dr Suite 100

Denton, Texas 76201

(940) 312-7266

(940) 312-7268

 

Yourhealthcareplace@ol.com

 

Monday - Friday 8am - 5pm

Closed daily for lunch from 

12:30pm - 1:30pm

Your Healthcare Place

Medication Management

At Your Healthcare Place, we offer many solutions to help you loose weight. At your initial visit, we determine what combination of diet, exercise, and medication will yield the best results for you. Patients are required to have a current EKG, labs to include a CBC, CMP and TSH (thyroid lab). Diabetics are required to have an A1c. 

 

Adipex diet pill works by affecting parts of the central nervous system, which effectively suppress hunger, and therefore, cravings. The Adipex diet pill is known to increase levels of energy within patients, which is ideally expended through exercise and being generally active.

Since the Adipex diet pill affects (and controls) the amount of signalling to the part of your brain that manages appetite, it is very effective in helping you manage how much you actually eat. The result of this effect, is that you will be more satisfied with less food when taking Adipex, more so than when you are not taking the diet pill. The other effect of Adipex, is that it increases your energy, so you can easily burn off the calories more easily. 

CONTRAVE® is a prescription-only, FDA-approved weight-loss pill believed to work on two areas of your brain—the hunger center and the reward system—to reduce hunger and help control cravings. CONTRAVE contains two medicines, bupropion and naltrexone.  CONTRAVE has a well-studied safety and tolerability profile. Three long-term (56 weeks) studies have shown that patients who add CONTRAVE lose approximately 2 to 4 times more weight than with diet and exercise alone. 3 In one study, patients who also participated in an intensive diet and exercise program and remained on CONTRAVE for a full year, lost 25 pounds on average.

BELVIQ and BELVIQ XR are FDA-approved prescription weight-loss medications that, when used with diet and exercise, can help some overweight (Body Mass Index [BMI] ≥27 kg/m²) adults with a weight-related medical problem, or obese (BMI ≥30 kg/m²) adults, lose weight and keep it off. BELVIQ and BELVIQ XR work by targeting a hunger receptor in the brain to help you feel full sooner. The precise way BELVIQ and BELVIQ XR produce feelings of satisfaction is not fully understood.Once-Daily BELVIQ XR is gradually released throughout the day and may fit into your schedule. BELVIQ and BELVIQ XR are not stimulants or narcotics. They are federally controlled substances with some risk of abuse or dependency.

Proven results with BELVIQ 10 mg twice daily

BELVIQ was clinically proven and tested in three clinical trials involving nearly 8,000 people. In one trial, BELVIQ was shown to deliver lasting weight loss up to 2 years.

 

 

Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Saxenda® should be used with a reduced-calorie meal plan and increased physical activity. These results were from a 56-week trial of adults with excess weight (BMI ≥27) with at least 1 weight-related condition, or obesity (BMI ≥30), not including patients with type 2 diabetes. On average, 27% of people on Saxenda® and 34% on placebo did not complete the study. In the study, 62% of patients on Saxenda® lost ≥5% of their body weight (vs 34% placebo) and 34% lost ≥10% body weight (vs 15% placebo). Significant weight loss was only evaluated at 56 weeks, as per study design.

Qsymia is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obese) (1) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia (1)